Literature DB >> 6778079

Comparative single-dose kinetics and effects of four sulfonylureas in healthy volunteers.

G Sartor, A Melander, B Scherstén, E Wåhlin-Boll.   

Abstract

The single-dose kinetics and effects of tolbutamide (500 mg), chlorpropamide (250 mg), glibenclamide (5 mg) and glipizide (5 mg) were compared in 7 healthy male volunteers by measurements of serum concentrations of the drugs and of plasma insulin and blood glucose. The drugs were administered both on an empty stomach and together with a standardized breakfast. The concentrations of tolbutamide and chlorpropamide were measured by gas chromatography, those of glipizide with high-pressure liquid chromatography, those of glibenclamide and insulin by radioimmunoassay and those of glucose by the hexokinase method. Glipizide and glibenclamide were more potent inducers of insulin release and blood glucose reduction than tolbutamide and chlorpropamide. As the concentrations of the former two drugs were in the range of nmol/l and those of the latter two in the mumol/l range, the findings support the notion that the intrinsic activity of the two second-generation sulfonylureas is at least 1 000 times greater than that of the two first-generation drugs. Glipizide seemed to be a more potent and more rapid insulin releaser than glibenclamide, but this may be secondary to biopharmaceutic differences between the two preparations. The bioavailability of glipizide was apparently greater than that of glibenclamide. Both glibenclamide (t 1/2 = 1.8 h) and glipizide (t 1/2 = 4.3 h) showed much shorter elimination half-lives than tolbutamide (7 h) and chlorpropamide (34 h). It seems probable, however, that these half-lives are not fully informative as to the duration of action of the drugs.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6778079     DOI: 10.1111/j.0954-6820.1980.tb01199.x

Source DB:  PubMed          Journal:  Acta Med Scand        ISSN: 0001-6101


  7 in total

1.  Pharmacokinetic and pharmacodynamic studies of glibenclamide in non-insulin dependent diabetes mellitus.

Authors:  S W Coppack; A F Lant; C S McIntosh; A V Rodgers
Journal:  Br J Clin Pharmacol       Date:  1990-06       Impact factor: 4.335

Review 2.  The relationship between the pharmacokinetics and pharmacodynamic effects of oral hypoglycaemic drugs.

Authors:  R E Ferner; S Chaplin
Journal:  Clin Pharmacokinet       Date:  1987-06       Impact factor: 6.447

3.  Chlorpropamide 2-hydroxylation is catalysed by CYP2C9 and CYP2C19 in vitro: chlorpropamide disposition is influenced by CYP2C9, but not by CYP2C19 genetic polymorphism.

Authors:  Ji-Hong Shon; Young-Ran Yoon; Min-Jung Kim; Kyoung-Ah Kim; Young-Chae Lim; Kwang-Hyeon Liu; Dong-Hoon Shin; Chung Han Lee; In-June Cha; Jae-Gook Shin
Journal:  Br J Clin Pharmacol       Date:  2005-05       Impact factor: 4.335

4.  Impaired effect of sulfonylurea following increased dosage.

Authors:  E Wåhlin-Boll; G Sartor; A Melander; B Scherstén
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

5.  Glibenclamide-associated hypoglycaemia: a report on 57 cases.

Authors:  K Asplund; B E Wiholm; F Lithner
Journal:  Diabetologia       Date:  1983-06       Impact factor: 10.122

6.  Effect of pirprofen on glibenclamide kinetics and response.

Authors:  P J Morrison; H J Rogers; R G Spector; I D Bradbrook; V A John
Journal:  Br J Clin Pharmacol       Date:  1982-07       Impact factor: 4.335

Review 7.  Pharmacokinetic-pharmacodynamic relationships of oral hypoglycaemic agents. An update.

Authors:  P Marchetti; R Navalesi
Journal:  Clin Pharmacokinet       Date:  1989-02       Impact factor: 6.447

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.